US · CDT
CDT Equity Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Naples, FL 34103
- Website
- conduitpharma.com
Price · as of 2025-12-31
$2.26
Market cap 936.98K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $17.01 | +652.65% |
| Graham-Dodd Method(GD) | $32.72 | +1,347.61% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $123,960.00 | ||||
| 2023 | $33,360.00 | ||||
| 2024 | $132.00 | ||||
| 2025 | $0.65 | $17.01 | $32.72 |
AI valuation
Our deep-learning model estimates CDT Equity Inc.'s (CDT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $2.26
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$17.01
+652.65% upside
Graham-Dodd
$32.72
+1,347.61% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CDT | CDT Equity Inc. | $2.26 | 936.98K | — | +653% | +1,348% | — | 0.11 | 0.02 | 0.01 | 3.22 | — | -0.15 | 37.98% | 11.63% | 8.75% | 37.77% | 28.00% | 13.64% | 1.09 | -6.81 | 1.93 | 1.22 | 3.14 | -12879.00% | — | -234691.00% | 845.61% | 0.51 | 19.40% | 30.80% | 3.40% | 30.80% | 3.22 | 4.65 | 0.37 | 1.88 |
| CCM | Concord Medical Services … | $3.64 | 530.04K | +8,914% | -53% | — | +156,680% | -0.01 | 0.00 | 0.01 | -10.37 | -0.19 | 0.00 | -20.62% | -138.60% | -80.28% | 29.62% | -42.92% | -10.20% | -1.72 | -2.75 | 0.46 | 0.19 | -10.75 | 355.00% | -2855.00% | 10618.00% | -18065.77% | -0.19 | -66.96% | 0.00% | 0.00% | 0.00% | -6.74 | -4.43 | 9.34 | -1.32 |
| COCH | Envoy Medical, Inc. | $0.72 | 15.07M | +3,147% | -23% | — | +2,867% | -1.16 | -1.39 | 116.08 | -2.03 | — | -1.39 | -229.78% | -8558.22% | -9242.22% | 217.79% | 381.46% | -226.68% | -1.04 | -23.60 | 1.24 | 0.84 | -0.72 | -4134.00% | -2880.00% | 977.00% | -72.47% | -2.38 | 374.98% | 9.37% | -10.90% | 9.37% | -2.09 | -2.13 | 179.09 | -39.33 |
| ENVB | Enveric Biosciences, Inc. | $2.35 | 1.4M | — | — | — | — | -0.10 | 0.57 | — | 0.14 | -0.07 | 0.59 | 0.00% | — | — | -539.57% | 1966.05% | -259.40% | 0.00 | — | 1.84 | 1.50 | 0.24 | 13535.00% | — | -4520.00% | -844.14% | -5.19 | 1576.99% | 0.00% | 0.00% | 118.40% | 0.14 | 0.17 | — | -57.63 |
| LIXT | Lixte Biotechnology Holdi… | $2.89 | 13.15M | — | — | — | — | -0.75 | 3.26 | — | -0.47 | — | 3.26 | 0.00% | — | — | -148.73% | 1699.47% | -131.50% | 0.00 | — | 3.26 | 3.26 | 0.29 | -4023.00% | — | -2629.00% | -117.26% | -9.94 | 1505.28% | 0.00% | 0.00% | 0.00% | -0.46 | -0.52 | — | -68.09 |
| NIVF | NewGenIvf Group Limited | $0.83 | 20.24K | +316,275% | +44,719% | — | — | -223.33 | -100.97 | 19.49 | 4469.74 | — | -100.97 | 33.63% | -21.35% | -9.66% | -35.29% | -20.66% | -11.76% | -2.89 | -1.49 | 1.17 | 1.04 | 106.02 | -27938.00% | 578.00% | 35301.00% | -7.86% | -3.04 | -300.37% | 0.00% | 0.00% | 0.00% | -93.49 | -13.04 | 19.96 | 12.77 |
| WORX | SCWorx Corp. | $0.33 | 1.37M | +13,567% | +79% | — | +2,775% | -1.19 | 0.30 | 0.45 | 5.66 | — | -1.00 | 24.95% | -42.13% | -38.01% | -27.24% | -30.41% | -18.00% | 0.01 | -12.09 | 0.27 | 0.26 | -0.26 | -7979.00% | -2143.00% | 3450.00% | -80.45% | -0.59 | -26.18% | 0.00% | 0.00% | 4.34% | -1.02 | -1.19 | 0.43 | -6.83 |
About CDT Equity Inc.
CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.
- CEO
- Andrew Regan
- Employees
- 6
- Beta
- 1.77
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($17.01 ÷ $2.26) − 1 = +652.65% (DCF, example).